Survivin supressant: A promising target for cancer therapy and pharmacological profiles of YM155

Folia Pharmacologica Japonica

Volumn 136, Issue 4, 2010, Pages 198-203

  Kita, Aya ^a   Nakahara, Takahito ^a   Takeuchi, Masahiro ^a   Kinoyama, Isao ^a   Yamanaka, Kentaro ^a   Minematsu, Tsuyoshi ^a   Mitsuoka, Keisuke ^a   Fushiki, Hiroshi ^a   Miyoshi, Sousuke ^a   Sasamata, Masao ^a   Miyata, Keiji ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 METHOXYETHOXY) 2 METHYL 3 (2 PYRAZINYLMETHYL)NAPHTHO[2,3 D]IMIDAZOLE 4,9 DIONE; ANTINEOPLASTIC AGENT; PROTEIN INHIBITOR; SURVIVIN; UNCLASSIFIED DRUG; BIRC5 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; MICROTUBULE ASSOCIATED PROTEIN; NAPHTHOQUINONE;

CANCER THERAPY; DRUG TARGETING; REVIEW; ANIMAL; DRUG ANTAGONISM; DRUG DESIGN; HUMAN; MOUSE; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; IMIDAZOLES; MICE; MICROTUBULE-ASSOCIATED PROTEINS; NAPHTHOQUINONES; TUMOR CELLS, CULTURED;

EID: 78149483084     PISSN: 00155691     EISSN: 13478397     Source Type: Journal    
DOI: 10.1254/fpj.136.198     Document Type: Review

References (13)

1. Mita AC, et al. Clin Cancer Res. 2008;14:5000-5005.
2. Altieri DC, et al. Nat Rev Cancer. 2008;8:61-70.
3. Srinivasa M. Mol Cell. 2008;30:123-135.
4. Ambrosini G, et al. Nat Med. 1997;3:917-921.
5. Nakahara T, et al. Cancer Res. 2007;67:8014-8021.
6. Straszewski-Chavez SL, et al. Endocr Rev. 2005;26:877-897.
7. McBride CB, et al. Expert Opin Ther Targets. 1999;3:391-411.
8. Salvesen GS, et al. Nat Rev Mol Cell Biol. 2002;3:401-410.
9. Minematsu T, et al. Drug Metab Dispos. 2009;37:619-628.
10. O'Connor DS, et al. Cancer Cell. 2002;2:43-54.
11. Bonavida B, et al. Oncogene. 2007;26:3629-3636.
12. Emmanouilides C, et al. Cancer Biother Radiopharm. 2002;17:621-630.
13. Chang CC. Proc Natl Acad Sci U S A. 2004;101:13239-13244.